Jazz Pharmaceuticals plc (NASDAQ:JAZZ) SVP Sells $152,703.00 in Stock

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) SVP Mary Elizabeth Henderson sold 1,410 shares of the firm’s stock in a transaction that occurred on Friday, September 6th. The stock was sold at an average price of $108.30, for a total value of $152,703.00. Following the transaction, the senior vice president now owns 14,531 shares in the company, valued at approximately $1,573,707.30. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Jazz Pharmaceuticals Trading Up 2.2 %

Shares of Jazz Pharmaceuticals stock opened at $108.79 on Friday. The firm has a market cap of $6.72 billion, a PE ratio of 22.43, a P/E/G ratio of 1.31 and a beta of 0.57. The company has a quick ratio of 2.02, a current ratio of 2.37 and a debt-to-equity ratio of 1.36. Jazz Pharmaceuticals plc has a fifty-two week low of $99.06 and a fifty-two week high of $137.38. The business’s fifty day moving average is $109.88 and its two-hundred day moving average is $111.71.

Hedge Funds Weigh In On Jazz Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of JAZZ. Rise Advisors LLC grew its position in Jazz Pharmaceuticals by 2,255.6% during the first quarter. Rise Advisors LLC now owns 212 shares of the specialty pharmaceutical company’s stock valued at $26,000 after acquiring an additional 203 shares during the period. Versant Capital Management Inc increased its position in Jazz Pharmaceuticals by 13,450.0% during the 2nd quarter. Versant Capital Management Inc now owns 271 shares of the specialty pharmaceutical company’s stock worth $29,000 after purchasing an additional 269 shares in the last quarter. Itau Unibanco Holding S.A. acquired a new stake in Jazz Pharmaceuticals during the 2nd quarter worth approximately $29,000. EverSource Wealth Advisors LLC raised its holdings in Jazz Pharmaceuticals by 55.1% in the second quarter. EverSource Wealth Advisors LLC now owns 273 shares of the specialty pharmaceutical company’s stock valued at $30,000 after buying an additional 97 shares during the period. Finally, GAMMA Investing LLC lifted its position in Jazz Pharmaceuticals by 65.5% during the second quarter. GAMMA Investing LLC now owns 293 shares of the specialty pharmaceutical company’s stock valued at $31,000 after buying an additional 116 shares in the last quarter. Institutional investors and hedge funds own 89.14% of the company’s stock.

Wall Street Analyst Weigh In

JAZZ has been the topic of a number of research reports. UBS Group lowered their target price on shares of Jazz Pharmaceuticals from $117.00 to $113.00 and set a “neutral” rating on the stock in a research report on Tuesday, July 2nd. StockNews.com upgraded shares of Jazz Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Thursday, August 1st. Morgan Stanley reduced their target price on shares of Jazz Pharmaceuticals from $160.00 to $150.00 and set an “equal weight” rating for the company in a report on Friday, July 12th. JPMorgan Chase & Co. raised their price target on Jazz Pharmaceuticals from $190.00 to $202.00 and gave the stock an “overweight” rating in a report on Monday, August 19th. Finally, Piper Sandler reduced their price objective on Jazz Pharmaceuticals from $188.00 to $166.00 and set an “overweight” rating for the company in a research note on Thursday, August 1st. Four research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $173.07.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.